A detailed history of Zuckerman Investment Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Zuckerman Investment Group, LLC holds 51,339 shares of BMY stock, worth $2.97 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
51,339
Previous 43,140 19.01%
Holding current value
$2.97 Million
Previous $1.79 Million 48.3%
% of portfolio
0.29%
Previous 0.21%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $325,172 - $424,298
8,199 Added 19.01%
51,339 $2.66 Million
Q2 2024

Aug 12, 2024

BUY
$40.25 - $52.99 $1.21 Million - $1.59 Million
30,000 Added 228.31%
43,140 $1.79 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $68,131 - $77,248
-1,420 Reduced 9.75%
13,140 $712,000
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $17,452 - $20,826
360 Added 2.54%
14,560 $747,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $37,049 - $41,427
-640 Reduced 4.31%
14,200 $824,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $15,179 - $17,216
-231 Reduced 1.53%
14,840 $1.03 Million
Q4 2022

Feb 15, 2023

SELL
$68.48 - $81.09 $209,480 - $248,054
-3,059 Reduced 16.87%
15,071 $1.08 Million
Q3 2022

Nov 04, 2022

BUY
$0.13 - $76.84 $1,244 - $735,589
9,573 Added 111.87%
18,130 $1.29 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $10,602 - $11,677
146 Added 1.74%
8,557 $659,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $543,325 - $633,390
-10,131 Reduced 54.64%
8,411 $524,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $2,485 - $2,911
42 Added 0.23%
18,542 $1.1 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $1.1 Million - $1.23 Million
18,500 New
18,500 $1.17 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Zuckerman Investment Group, LLC Portfolio

Follow Zuckerman Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zuckerman Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zuckerman Investment Group, LLC with notifications on news.